Application Note

Minimizing On-Column Monoclonal Antibody Aggregate Formation

By Giorgio Carta, Payal Khandelwal, and Mark Snyder

Minimizing On-Column Monoclonal Antibody Aggregate Formation

The formation of aggregates is a common occurrence during monoclonal antibody (mAb) purification and can happen for several reasons.  Aggregates are undesirable due to the possibility of altered pharmacodynamics, pharmacokinetics, and/or increased immunogenicity. Generally, the formation of aggregates is shown to be product or process related.  Here we show how on-column aggregate formulation is dependent on the resin type and on the resin's interactions with the mAb loaded.  Among the various resins tested, Nuvia™ HR-S Resin, a high-resolution cation exchanger, demonstrated the lowest proportion of on-column aggregate formation with two mAbs.  On-column aggregate formation can therefore be minimized by proper resin screening and subsequent optimization of resin type used for purification process development.

VIEW THE APPLICATION NOTE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: